Cancer researchers got a rare standing ovation at this year’s American Society of Clinical Oncology meeting in Chicago, and it was for a cancer that’s resisted real progress for decades. The pancreatic cancer result behind the ovation The drug is daraxonrasib, a once-daily pill, and the trial behind it, RASolute 302, was presented by Dr. […] The post A pancreatic cancer pill just nearly doubled survival time appeared first on Rolling Out .
Install the app today!
Get in touch with us
Reach out to the Hayti team about
collaborating or working together.